Interleukin-1 Receptor-Like 1 Protein
-
Subject Areas on Research
-
A multimarker multi-time point-based risk stratification strategy in acute heart failure: results from the RELAX-AHF trial.
-
Analysis of BAG3 plasma concentrations in patients with acutely decompensated heart failure.
-
Analytical and clinical evaluation of a novel high-sensitivity assay for measurement of soluble ST2 in human plasma--the Presage ST2 assay.
-
Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab.
-
Association of novel biomarkers of cardiovascular stress with left ventricular hypertrophy and dysfunction: implications for screening.
-
Associations of Circulating Growth Differentiation Factor-15 and ST2 Concentrations With Subclinical Vascular Brain Injury and Incident Stroke.
-
Biomarker-assist score for reverse remodeling prediction in heart failure: The ST2-R2 score.
-
Biomarker-based risk prediction in the community.
-
Biomarkers in acute heart failure.
-
Biomarkers of cardiovascular stress and incident chronic kidney disease.
-
Biomarkers of cardiovascular stress and subclinical atherosclerosis in the community.
-
Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure.
-
Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure.
-
Combined Measurement of Soluble ST2 and Amino-Terminal Pro-B-Type Natriuretic Peptide Provides Early Assessment of Severity in Cardiogenic Shock Complicating Acute Coronary Syndrome.
-
Common genetic variation at the IL1RL1 locus regulates IL-33/ST2 signaling.
-
Comparison between admission natriuretic peptides, NGAL and sST2 testing for the prediction of worsening renal function in patients with acutely decompensated heart failure.
-
Development and evaluation of multi-marker risk scores for clinical prognosis.
-
Distribution and clinical correlates of the interleukin receptor family member soluble ST2 in the Framingham Heart Study.
-
Emerging biomarkers in heart failure.
-
Found in translation soluble ST2 and heart disease.
-
Genome-wide association studies in asthma: what they really told us about pathogenesis.
-
Head-to-head comparison of serial soluble ST2, growth differentiation factor-15, and highly-sensitive troponin T measurements in patients with chronic heart failure.
-
IL-33/ST2 signaling excites sensory neurons and mediates itch response in a mouse model of poison ivy contact allergy.
-
IL233, A Novel IL-2 and IL-33 Hybrid Cytokine, Ameliorates Renal Injury.
-
Importance of biomarkers for long-term mortality prediction in acutely dyspneic patients.
-
Importance of rigorous evaluation in comparative biomarker studies.
-
Independent and incremental prognostic value of multimarker testing in acute dyspnea: results from the ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) study.
-
Interleukin receptor family member ST2 concentrations in patients following heart transplantation.
-
Long-term IL-33-producing epithelial progenitor cells in chronic obstructive lung disease.
-
Measurement of multiple biomarkers in advanced stage heart failure patients treated with pulmonary artery catheter guided therapy.
-
Measurement of the interleukin family member ST2 in patients with acute dyspnea: results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study.
-
Meta-Analysis of Soluble Suppression of Tumorigenicity-2 and Prognosis in Acute Heart Failure.
-
Multimarker Risk Stratification in Patients With Acute Myocardial Infarction.
-
Novel Heart Failure Biomarkers Predict Improvement of Mitral Regurgitation in Patients Receiving Cardiac Resynchronization Therapy-The BIOCRT Study.
-
Plasma Concentrations of Soluble Suppression of Tumorigenicity-2 and Interleukin-6 Are Predictive of Successful Liberation From Mechanical Ventilation in Patients With the Acute Respiratory Distress Syndrome.
-
Prevalence, Neurohormonal Correlates, and Prognosis of Heart Failure Stages in the Community.
-
Prognostic Value of Baseline and Changes in Circulating Soluble ST2 Levels and the Effects of Nesiritide in Acute Decompensated Heart Failure.
-
Prognostic Value of Soluble Suppression of Tumorigenicity-2 in Chronic Heart Failure: A Meta-Analysis.
-
Prognostic utility of novel biomarkers of cardiovascular stress in patients with aortic stenosis undergoing valve replacement.
-
Prognostic utility of novel biomarkers of cardiovascular stress: the Framingham Heart Study.
-
Prognostic value of sST2 added to BNP in acute heart failure with preserved or reduced ejection fraction.
-
Prognostic value of sST2 and galectin-3 for death relative to renal function in patients hospitalized for heart failure.
-
Pulmonary Production of Soluble ST2 in Heart Failure.
-
Relation between soluble ST2, growth differentiation factor-15, and high-sensitivity troponin I and incident atrial fibrillation.
-
Relations of circulating GDF-15, soluble ST2, and troponin-I concentrations with vascular function in the community: The Framingham Heart Study.
-
ST2 Predicts Mortality and Length of Stay in a Critically Ill Noncardiac Intensive Care Unit Population.
-
ST2 and mortality in non-ST-segment elevation acute coronary syndrome.
-
ST2 and prognosis in acutely decompensated heart failure: the International ST2 Consensus Panel.
-
ST2 as a cardiovascular risk biomarker: from the bench to the bedside.
-
ST2 in Pulmonary Disease.
-
ST2 pathogenetic profile in ambulatory heart failure patients.
-
ST2 testing for chronic heart failure therapy monitoring: the International ST2 Consensus Panel.
-
ST2: a novel biomarker for heart failure.
-
ST2: a novel remodeling biomarker in acute and chronic heart failure.
-
Sequence variants affecting eosinophil numbers associate with asthma and myocardial infarction.
-
Serial Echocardiographic Characteristics, Novel Biomarkers and Cachexia Development in Patients with Stable Chronic Heart Failure.
-
Serial monitoring of soluble interleukin family member ST2 in patients with acutely decompensated heart failure.
-
Serial sampling of ST2 predicts 90-day mortality following destabilized heart failure.
-
Serum levels of the interleukin-1 receptor family member ST2, cardiac structure and function, and long-term mortality in patients with acute dyspnea.
-
Soluble ST2 and galectin-3 in heart failure.
-
Soluble ST2 in Heart Failure.
-
Soluble ST2 in ambulatory patients with heart failure: Association with functional capacity and long-term outcomes.
-
Soluble ST2 is a marker for acute cardiac allograft rejection.
-
Soluble ST2 monitoring provides additional risk stratification for outpatients with decompensated heart failure.
-
Soluble ST2 plasma concentrations predict 1-year mortality in acutely dyspneic emergency department patients with pulmonary disease.
-
Soluble ST2 predicts elevated SBP in the community.
-
Soluble concentrations of the interleukin receptor family member ST2 and β-blocker therapy in chronic heart failure.
-
State of the Art: Newer biomarkers in heart failure.
-
Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction.
-
The Dynamics of Cardiovascular Biomarkers in non-Elite Marathon Runners.
-
The International ST2 Consensus Panel: Introduction.
-
The biology of ST2: the International ST2 Consensus Panel.
-
The prognostic value of plasma soluble ST2 in hospitalized Chinese patients with heart failure.
-
Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction.